SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (692)5/11/2006 12:05:04 AM
From: rkrw  Read Replies (1) | Respond to of 933
 
Nice work. Thanks for laying it out. I think hsp90 is a heck of a target. Tickles a who's who of kinases. No surprise there's a great amount of interest in the space. So I think this is one to watch. Should infy have a higher market cap?

Good insights on the new management, sometimes that seems to be the way it works, out with the old, new cleans out all those little overhangs that get in the way of what they're in business for.



To: keokalani'nui who wrote (692)5/25/2006 10:27:38 PM
From: zeta1961  Read Replies (1) | Respond to of 933
 
KOS 1584..a very detailed PK, toxicity, MTD finding abstract..no survival stats except there are 4 patients(3 of which were PD pre study) with 'extended' stable disease..they are folk with ovarian and colon cancer..

Elisabeth


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News